Clinical Trial Search

Primary: Number of Participants With Composite Neonatal Morbidity — 149; 163; 62; 55 Participants — p=0.14

Primary: Weight Loss — 0; 0; 2 Participants

Primary: Change in Weight From Baseline — -1.4; -0.8 kilograms

Primary: Normalization of Glucose Levels — 9; 2; 4 Participants — p=.035

Primary: Large for Gestational Age (LGA) Infant — 34; 35; 28; 34 Participants — p=0.668

Primary: Number of Participants With a Composite Perinatal Outcome — 235; 261 Participants

Primary: Changes in Fasting Glucose — 10.4; 1.6 mg/dL

Primary: Proportion of Women Who Are Eligible, Screened, Enroll and Remain in the Study — 25; 26 Participants — p=0.9

Primary: The Concentration of Serum FGF19 — 65.96; 124.47 pg/mL

Primary: Number of Patients With Prescriptions of SGLT2i or GLP1-RA at Any Time — 81; 47 Participants

Primary: Cholesterol — 204; 201 mg/dl

Primary: Large for Gestational Age (LGA) — 23; 17 Participants

Primary: Change in HbA1c — -0.25; -0.4 Percent — p=0.2539

Primary: Mean Fetal Weight at Birth — 3355; 3322 grams

Primary: Number of Neonates That Show Composite Adverse Neonatal Outcome — 130; 114 Participants

Primary: Portion of Study Participants Reporting Greater Utility From AGP vs. Traditional Glucose Data Reports — 35; 29; 10 participants

Primary: Compliance With Requirements for Frequency of Glucose Measures — 3.1 number of glucose checks per pt per day

Primary: Change in Percentage of CGM Glucose Readings > 120 mg/dL — 25.0; 21.5; 16.9; 21.7 percentage of CGM readings

Primary: The Primary Outcome is the Area Under the Stimulated C-peptide Curve (AUC) at the One Year Visit — 0.448; 0.350; 0.418 nmol/L — p=0.98

Primary: Injection Site Skin Reactions — 4 events

Primary: Retinal Nerve Fiber Layer (RNFL) Thickness Correlation Width Global Bruch's Membrane Opening-minimum Rim Width (BMO-MRW) — 0.70 correlation coefficient

Primary: Insulin Secretion-Sensitivity Index (IS-SI) — 418.4; 333 index — p=<0.04

Primary: Primary Composite Outcome — 150; 167 Participants — p=0.13

Primary: HBA1c at One Year — 8.5; 7.7; 7.9; 7.9 percentage of HbA1c — p=0.027

Primary: Change in Body Weight — -21.5; -12.5; -4.4 kilograms — p=<0.032

Primary: Delay Interval (Days From Randomization Until the Provider Signs the Order for a hgbA1C Level). — 12; 104 Days

Primary: Glucose Levels of the Groups in Pregnant Women With Impaired Blood Sugar and/or Gestational DM — 111.67; 154; 83.06; 88.15 mg/dl

Primary: Change From Baseline in Insulin Secretion Rate (ISR) Normalized to Ambient Plasma Glucose — 2.14; 1.49; 0.53; 2.95 (ng/min) / (mg/dL) — p=<0.001

Primary: Percentage of Time Spent in Hyperglycemia > 180 mg/dL — 35.47; 35.25 percentage of time spent > 180mg/dL

Primary: Glycemic Control — 109.5; 107.4 mg/dL